Thaminda brings more than two decades of global biotechnology and pharmaceutical leadership experience, with a focus on building companies and advancing innovative therapeutics. Prior to joining Anaveon, he served as Chief Business Officer at CureVac, where he played a central role in the company’s transformation and its acquisition by BioNTech. He previously held senior leadership roles at Sanofi, Affini-T Therapeutics, BioMarin, and Amgen, leading strategic transactions and partnerships across multiple therapeutic areas.

Throughout his career, Thaminda has operated at the intersection of science and strategy—helping translate breakthrough biology into differentiated medicines and scalable platforms. He is also a Venture Partner at Entrée Bio, a premier biotechnology investment fund incubated within Entrée Capital. Thaminda holds a B.A. in Cellular Biology from Berea College and earned his M.S. in Immunology and MBA in Finance from the University of Rochester.

Dr. Eric Zanelli has more than 25 years of executive and scientific experience in the biotechnology industry. Since 2025, Eric has served as a scientific advisor to Certa Therapeutics, a company developing therapies for fibrosis. In 2018, he co-founded Allievex Corp. and led its research activities through 2024, overseeing nonclinical and translational development programs focused on rare neurological diseases.

Previously, Eric served as Senior Scientific Advisor at CoLucid Pharmaceuticals (NASDAQ: CLCD), supporting the development of lasmiditan for acute migraine treatment. He also held senior scientific leadership roles at Peptimmune, Praecis Pharmaceuticals, and Cardion AG, and founded Déclion Holdings, a biotechnology company focused on neurodegenerative diseases.

Eric is the co-author of more than 50 scientific publications and an inventor on multiple patent families. Before joining industry, he conducted academic research at Leiden University Medical Center and the Mayo Clinic, focusing on autoimmune diseases and genetics. He earned a PhD in Immunology from Aix-Marseille University in France.

Dr. Jill Marie Jene brings more than 25 years of leadership experience in biopharmaceutical strategy, business development, and corporate growth, with a focus on improving patients’ lives while building high-value healthcare companies. Over the course of her career, Jill has led more than 50 transactions valued at over $6 billion across oncology, immunology, neurology, pain, and women’s health.

She has held senior leadership roles at Adamas Pharmaceuticals, PDL Biopharma, twoXAR, and Depomed, leading strategic partnerships and corporate development initiatives. Earlier in her career, she worked at Cell Genesys, 3M Pharmaceutical Division, and Baxter International.

In 2022, Jill founded Jene Advisors, a firm supporting biotechnology companies in strategy, partnerships, and capital access. She also serves on the board of Lipocine Inc.

Jill earned a B.S. from Bradley University, a Ph.D. in chemistry from Northwestern University, and an MBA from DePaul University.

Tom Mathers currently serves as Executive Chairman and Interim CEO of Aer Therapeutics, which is developing novel therapies for serious airway diseases, and as Vice Chairman of Certa Therapeutics, focused on fibrosis. He is also Treasurer and Executive Committee member of the Biotechnology Innovation Organization (BIO), where he contributes to advocacy, regulatory policy, capital formation, bioethics, and intellectual property initiatives.

In 2019, he founded Allievex Corp., a clinical-stage company focused on neuronopathic lysosomal storage diseases and served as President and CEO until its acquisition by Spruce Biosciences in 2024. Previously, as President and CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD), he led the development of lasmiditan for acute migraine treatment through its acquisition by Eli Lilly in 2017 for nearly $1 billion.

Earlier in his career, Tom held senior leadership roles at Genzyme, Peptimmune, Cell Based Delivery, and Cardion AG. He graduated from the United States Military Academy at West Point and served as a Captain and AH-64 Apache helicopter pilot in the U.S. Army during the Gulf War.